The Role of Antibiotic Treatment in Patients With Acute Mild Cholecystitis - A Prospective Randomized Controlled Trial
Launched by HADASSAH MEDICAL ORGANIZATION · Nov 11, 2007
Trial Information
Current as of July 22, 2025
Completed
Keywords
ClinConnect Summary
Cholelithiasis and inflammatory biliary tract disease constitute a major health problem in western countries. Acute cholecystitis is the third major cause of emergency admission to a surgical ward and its incidence increases with increasing age. Acute cholecystitis is defined as acute inflammation of the gallbladder which is commonly caused by gallstones which are impacted in the cystic duct. The treatment of acute cholecystitis varies between different medical centers around the world. In some hospitals, mainly in the US, the most common treatment is early laparoscopic cholecystectomy with...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Patients with the diagnosis of mild acute cholecystitis that meet the following:
- 1. Sonographic (or CT) findings:
- • 1. cholelithiasis or sludge and
- • 2. wall thickening \> 4 mm, and
- • 3. positive sonographic Murphy sign,
- • 4. distended gallbladder (optional)
- • 5. pericystic fluid (optional)
- 2. Additional one of the following:
- • 1. epigastric or RUQ pain
- • 2. fever \> 38.0
- • 3. WBC \> 10,000
- Exclusion criteria:
- • 1. Age - less than 18 or above 70
- • 2. Pregnant females
- • 3. Unconsentable patients
- • 4. NYHA \> 3
- • 5. Use of steroids or immunosuppression
- • 6. Onset of typical abdominal pain for over than 72 hours
- • 7. Hemodynamic instability
- • 8. Fever \> 39 or chills
- • 9. Palpable inflammatory RUQ mass
- • 10. Presence of peritonitis on physical examination
- • 11. WBC \> 18,000
- • 12. Diastase \> 200 (NL 20-100)
- • 13. Bilirubin \> 85 (X5 the norm)
- • 14. Multi organ failure
About Hadassah Medical Organization
Hadassah Medical Organization (HMO) is a leading healthcare institution based in Jerusalem, Israel, renowned for its commitment to advancing medical research and improving patient care. As a prominent clinical trial sponsor, HMO leverages its state-of-the-art facilities and multidisciplinary expertise to conduct innovative research across various therapeutic areas. The organization is dedicated to fostering collaboration between clinical researchers, healthcare professionals, and academic institutions, ensuring the highest standards of ethical practice and scientific rigor. HMO's mission is to translate groundbreaking research into effective treatments, ultimately enhancing health outcomes for diverse populations both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jerusalem, , Israel
Patients applied
Trial Officials
Haggi Mazeh, M.D.
Principal Investigator
Hadassah Medical Organization
Herbert R Freund, M.D.
Study Director
Hadassah Medical Organization
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials